Press releases

27 Apr 2023

UCB Receives Positive CHMP Opinions for Bimekizumab for the Treatment of Adults with Psoriatic Arthritis and Axial Spondyloarthritis in the European Union

20 Apr 2023

UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

13 Apr 2023

UCB’s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in prestigious The Lancet Neurology Journal

24 Mar 2023

Acquisition of own shares

18 Mar 2023

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

17 Mar 2023

Acquisition of own shares

Press releases

Press releases

Search Press releases

UCB Receives Positive CHMP Opinions for Bimekizumab for the Treatment of Adults with Psoriatic Arthritis and Axial Spondyloarthritis in the European Union

UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

UCB’s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in prestigious The Lancet Neurology Journal

Acquisition of own shares

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Acquisition of own shares

Choose a Country

UCB and Ailux Biologics Join Forces to Transform Biologics Research

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in...

RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two...

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB completes sale of established brands and updates 2024 financial guidance

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB Receives Positive CHMP Opinions for Bimekizumab for the Treatment of Adults with Psoriatic Arthritis and Axial Spondyloarthritis in the European Union

UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

UCB’s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in prestigious The Lancet Neurology Journal

Acquisition of own shares

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Acquisition of own shares

Choose a Country